Follow-up Schedule for Patients With Sentinel Node–negative Cutaneous Melanoma (The MELFO Study)-Reference-Cited by-同舟云学术

Follow-up Schedule for Patients With Sentinel Node–negative Cutaneous Melanoma (The MELFO Study)

Published:2022-07-22 Issue:4 Volume:276 Page:e208-e216
ISSN:0003-4932
Container-title:Annals of Surgery
language:en
Short-container-title:

Author:

Moncrieff Marc D.,Bastiaannet Esther,Underwood Beverly,Francken Anne Brecht,Garioch Jennifer,Damude Samantha,Heaton Martin,Deckers Eric A.,Patel Nakul,Hoekstra-Weebers Josette E.,Hoekstra Harald J.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Surgery

Reference22 articles.

1. Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003–2018): a nationwide population-based study;Leeneman;Eur J Cancer

2. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual;Gershenwald;CA Cancer J Clin,2017

3. Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: a UK consensus statement;Peach;J Plast Reconstr Aesthet Surg,2019

4. Recurrence of melanoma after a negative sentinel node biopsy: predictors and impact of recurrence site on survival;Thomas;Ann Surg Oncol,2019

5. Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma;Turner;J Clin Oncol,2011

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and Imaging Follow-Up for High-Risk Cutaneous Melanoma: Current Evidence and Guidelines;Cancers;2024-07-18

2. Surveillance evaluations in patients with stage I, II, III, or resectable IV melanoma who were treated with curative intent: A systematic review;Surgical Oncology;2024-06

3. An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Surveillance Strategies in Patients with Stage I, II, III or Resectable IV Melanoma Who Were Treated with Curative Intent;Clinical Oncology;2024-04

4. Service implications of the revised 2022 National Institute for Health and Care Excellence (NICE) follow-up guidelines for stage IA–IIC melanoma;British Journal of Surgery;2024-01